Could Prevention Data Give REGEN-COV Competitive Leg Up?
Executive Summary
Could Prevention Data Give REGEN-COV Competitive Leg Up?
You may also be interested in...
Coronavirus Update: As Pfizer/BioNTech Begin Omicron Vaccine Tests, Regulators Want To Explore Multivalent Route
Pfizer explores options for new vaccine update, Veklury expands to non-hospitalized patients but Regeneron and Lilly therapies stopped in face of Omicron efficacy drop-off.
COVID-19 Products Had Strong 2021, But Omicron Casts Shadow Over 2022
Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.
Coronavirus Update: Pfizer/BioNTech Vaccine Effective Against Omicron
Also, AstraZeneca scores an emergency use authorization from the FDA for its COVID-19 PrEP antibody Evusheld, while Merck files for Japanese approval of molnupiravir.